The GeparDouze trial is a randomized controlled study investigating the addition of perioperative atezolizumab, a PD-L1 inhibitor, to standard neoadjuvant chemotherapy in patients with early triple-negative breast cancer (TNBC). The primary endpoint was event-free survival (EFS), with secondary endpoints including pathologic complete response (pCR) rate, overall survival (OS), and safety.

While the addition of atezolizumab significantly increased the pCR rate, this did not translate into an improvement in EFS. The safety profile observed was consistent with the known adverse effects of immunotherapy and chemotherapy. These findings, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), were extensively discussed by experts including Dr. José Sandoval and Dr. Matteo Lambertini, highlighting the complexities of integrating immunotherapy into early TNBC treatment paradigms.